Theseus Pharmaceuticals, Inc. (THRX)
Feb 14, 2024 - THRX was delisted (reason: acquired by Concentra Biosciences)
4.060
0.00 (0.00%)
Inactive · Last trade price
on Feb 13, 2024
Company Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients.
Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors.
The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer.
Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer.
The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Theseus Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Oct 7, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Dr. Iain D. Dukes DPHIL, M.A. |
Contact Details
Address: 314 Main Street, Suite 04-200 Cambridge, Massachusetts 02142 | |
| Phone | (857) 400-9491 |
| Website | theseusrx.com |
Stock Details
| Ticker Symbol | THRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001745020 |
| CUSIP Number | 88369M101 |
| ISIN Number | US88369M1018 |
| Employer ID | 83-0712806 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Iain D. Dukes DPHIL, M.A. | Co-Founder and Chairman |
| Bradford D. Dahms | President, Chief Financial Officer and Director |
| Kristine Callahan CPA | Vice President and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 14, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 14, 2024 | POS AM | Post-Effective amendments for registration statement |
| Feb 14, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC TO-T/A | Filing |
| Feb 14, 2024 | SC 14D9/A | Filing |
| Feb 14, 2024 | 25-NSE | Filing |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 7, 2024 | SC 14D9/A | Filing |
| Feb 7, 2024 | SC TO-T/A | Filing |